Movement Alert｜Natera Pre-Market Rise 13.42%, Q2 Revenue Significantly Beats Expectations with Full-Year Guidance Raised

Market Focus08-07 19:15

On August 7, Natera rose 13.42% in pre-market trading, trading at $300.94/share. The surge was driven by the company's Q2 earnings release, which significantly exceeded market expectations on both revenue and profitability metrics, accompanied by an upward revision to full-year guidance.

Natera reported Q2 revenue of $752.8 million, up 37.7% year-over-year and substantially above the consensus estimate of $661.2 million. Adjusted loss per share narrowed to $0.47 from $0.74 a year earlier, beating the Street estimate of $0.49. The company raised its full-year revenue guidance to $2.85 billion-$2.91 billion, up from the prior range of $2.74 billion-$2.82 billion and above the analyst consensus of $2.80 billion.

In addition to the earnings beat, multiple recent developments have bolstered investor confidence. The company's core Signatera MRD test secured EU IVDR certification, Japan PMDA regulatory clearance for colorectal cancer, and an NCCN Category 1 recommendation in bladder cancer. Strategic partnerships with Aveta Biomics and Eledon Pharmaceuticals for Phase 3 clinical trials further reinforce Natera's leadership in molecular residual disease testing.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142356731?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142356731","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Natera Pre-Market Rise 13.42%, Q2 Revenue Significantly Beats Expectations with Full-Year Guidance Raised","media":"Market Focus","content":"<p><p>On August 7, Natera rose 13.42% in pre-market trading, trading at $300.94/share. The surge was driven by the company's Q2 earnings release, which significantly exceeded market expectations on both revenue and profitability metrics, accompanied by an upward revision to full-year guidance.</p><p>Natera reported Q2 revenue of $752.8 million, up 37.7% year-over-year and substantially above the consensus estimate of $661.2 million. Adjusted loss per share narrowed to $0.47 from $0.74 a year earlier, beating the Street estimate of $0.49. The company raised its full-year revenue guidance to $2.85 billion-$2.91 billion, up from the prior range of $2.74 billion-$2.82 billion and above the analyst consensus of $2.80 billion.</p><p>In addition to the earnings beat, multiple recent developments have bolstered investor confidence. The company's core Signatera MRD test secured EU IVDR certification, Japan PMDA regulatory clearance for colorectal cancer, and an NCCN Category 1 recommendation in bladder cancer. Strategic partnerships with Aveta Biomics and Eledon Pharmaceuticals for Phase 3 clinical trials further reinforce Natera's leadership in molecular residual disease testing.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Natera Pre-Market Rise 13.42%, Q2 Revenue Significantly Beats Expectations with Full-Year Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Natera Pre-Market Rise 13.42%, Q2 Revenue Significantly Beats Expectations with Full-Year Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 19:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, Natera rose 13.42% in pre-market trading, trading at $300.94/share. The surge was driven by the company's Q2 earnings release, which significantly exceeded market expectations on both revenue and profitability metrics, accompanied by an upward revision to full-year guidance.</p><p>Natera reported Q2 revenue of $752.8 million, up 37.7% year-over-year and substantially above the consensus estimate of $661.2 million. Adjusted loss per share narrowed to $0.47 from $0.74 a year earlier, beating the Street estimate of $0.49. The company raised its full-year revenue guidance to $2.85 billion-$2.91 billion, up from the prior range of $2.74 billion-$2.82 billion and above the analyst consensus of $2.80 billion.</p><p>In addition to the earnings beat, multiple recent developments have bolstered investor confidence. The company's core Signatera MRD test secured EU IVDR certification, Japan PMDA regulatory clearance for colorectal cancer, and an NCCN Category 1 recommendation in bladder cancer. Strategic partnerships with Aveta Biomics and Eledon Pharmaceuticals for Phase 3 clinical trials further reinforce Natera's leadership in molecular residual disease testing.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTRA","symbol_name":"Natera, Inc.","start_time":0,"source_url":"","article_id":"1142356731","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142356731","pubTimestamp":1786101337,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, Natera rose 13.42% in pre-market trading, trading at $300.94/share. The surge was driven by the company's Q2 earnings release, which significantly exceeded market expectations on both...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTRA":"Natera, Inc."},"translate_title":"走势警报|Natera 盘前上涨 13.42%，第二季度收入大幅超出预期，全年指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1},"content_text":"On August 7, Natera rose 13.42% in pre-market trading, trading at $300.94/share. The surge was driven by the company's Q2 earnings release, which significantly exceeded market expectations on both revenue and profitability metrics, accompanied by an upward revision to full-year guidance.Natera reported Q2 revenue of $752.8 million, up 37.7% year-over-year and substantially above the consensus estimate of $661.2 million. Adjusted loss per share narrowed to $0.47 from $0.74 a year earlier, beating the Street estimate of $0.49. The company raised its full-year revenue guidance to $2.85 billion-$2.91 billion, up from the prior range of $2.74 billion-$2.82 billion and above the analyst consensus of $2.80 billion.In addition to the earnings beat, multiple recent developments have bolstered investor confidence. The company's core Signatera MRD test secured EU IVDR certification, Japan PMDA regulatory clearance for colorectal cancer, and an NCCN Category 1 recommendation in bladder cancer. Strategic partnerships with Aveta Biomics and Eledon Pharmaceuticals for Phase 3 clinical trials further reinforce Natera's leadership in molecular residual disease testing.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142356731","isCrawlerRequest":true}